Prednisone
Active form: Prednisolone.
JFDA label: Prednisone 5 Tablets
Mechanism of Action
Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist
| Target | Action | Gene / class |
|---|---|---|
| Glucocorticoid receptor efficacy | AGONIST | NR3C1 |
Indications
Approved
- Allergic states
- Delayed release only
- Delayed-release only
- Dermatologic diseases
- Endocrine disorders
- GI diseases
- Hematologic disorders
- Immediate-release only
- Maintenance therapy
- Miscellaneous
- Neoplastic diseases
- Nervous system (delayed-release only)
- Ophthalmic diseases
- Renal diseases
- Respiratory diseases
- Rheumatic disorders
- Short-term therapy
Off-label
- Acute exacerbation of chronic obstructive pulmonary disease (COPD)
- Adjunctive therapy for pain management in immunocompetent patients with herpes zoster
- Autoimmune hepatitis
- Bell palsy
- Duchenne muscular dystrophy
- Giant cell arteritis
- Glucocorticoid remediable aldosteronism, treatment
- Graves orbitopathy
- Pericarditis
- Prostate cancer (metastatic)
- Takayasu arteritis
- Thyroiditis, subacute
- Thyrotoxicosis (type 2 amiodarone-induced)
Contraindications
Source: Lexicomp
- Hypersensitivity to prednisone or any component of the formulation Absolute
- administration of live or live attenuated vaccines with immunosuppressive doses of prednisone Absolute
- systemic fungal infections Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty Absolute
Adverse Reactions
Cardiac disorders (2)
Not Known Cardiac failure (in susceptible patients) · hypertension
Nervous system disorders (7)
Not Known Emotional lability · headache · increased intracranial pressure (with papilledema) · myasthenia · psychiatric disturbance (including euphoria, insomnia, mood swings, personality changes, severe depression) · seizure · vertigo
Hepatobiliary disorders (3)
Not Known Increased serum alkaline phosphatase · increased serum ALT · increased serum AST
Blood and lymphatic system disorders (3)
Not Known Bruise · Kaposi’s sarcoma · petechia
Immune system disorders (2)
Not Known Anaphylaxis · hypersensitivity reaction
Metabolism and nutrition disorders (10)
Not Known Cushing’s syndrome · decreased serum potassium · diabetes mellitus · fluid retention · growth suppression (children) · hypokalemic alkalosis · hypothyroidism (enhanced) · menstrual disease · negative nitrogen balance (due to protein catabolism) · sodium retention
Gastrointestinal disorders (5)
Not Known Abdominal distention · carbohydrate intolerance · pancreatitis · peptic ulcer (with possible perforation and hemorrhage) · ulcerative esophagitis
Skin and subcutaneous tissue disorders (4)
Not Known Diaphoresis · facial erythema · skin atrophy · urticaria
Musculoskeletal and connective tissue disorders (7)
Not Known Amyotrophy · aseptic necrosis of bones (femoral and humeral heads) · osteoporosis · pathological fracture (long bones) · rupture of tendon (particularly Achilles tendon) · steroid myopathy · vertebral compression fracture
Eye disorders (4)
Not Known Exophthalmos · glaucoma · increased intraocular pressure · subcapsular posterior cataract
Infections and infestations (1)
Not Known Infection
General disorders and administration site conditions (1)
Not Known Wound healing impairment
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Adrenal suppression
May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving >20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections.
Anaphylactoid reactions
Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.
Immunosuppression
Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used to treat viral hepatitis or cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination and fatalities have occurred.
Kaposi sarcoma
Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).
Myopathy
Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.
Psychiatric disturbances
Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression or frank psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Disease-related concerns:
Cardiovascular disease
Use with caution in patients with HF and/or hypertension; long-term use has been associated with electrolyte disturbances, fluid retention, and hypertension. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.
Diabetes
Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.
Gastrointestinal disease
Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific]) due to perforation risk.
Head injury
Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.
Hepatic impairment
Use with caution in patients with hepatic impairment, including cirrhosis; effects may be enhanced.
Myasthenia gravis
Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.
Ocular disease
Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.
Osteoporosis
Use with caution in patients with or who are at risk for osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.
Renal impairment
Use with caution in patients with renal impairment; fluid retention may occur.
Seizure disorders
Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.
Thyroid disease
Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Concurrent drug therapy issues:
Drug-drug interactions
Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations:
Elderly
Use with caution in the elderly with the smallest possible effective dose for the shortest duration.
Pediatric
May affect growth velocity; growth and development should be routinely monitored in pediatric patients. Dosage form specific issues:
Benzyl alcohol and derivatives
Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.
Propylene glycol
Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007). Other warnings/precautions:
Discontinuation of therapy
Withdraw therapy with gradual tapering of dose.
Stress
Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).
Pregnancy & Lactation
Pregnancy
Caution
As for prednisolone. Use lowest effective dose
Lactation
Prednisone and its metabolite, prednisolone, are present in breast milk. Actual concentrations are dependent upon maternal dose (Berlin 1979; Katz 1975; Sagraves 1981). Peak concentrations of prednisone and prednisolone in breast milk occur ~2 hours after an oral maternal dose (Berlin 1979; Sagraves 1981); the half-life in breast milk is 1.9 hours (prednisone) and 4.2 hours (prednisolone) (Sagraves 1981). In a study which included six mother-infant pairs, adverse events were not observed in nu
Monitoring
| Clinical pearl | Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); Hgb, occult blood loss; chest x-ray (at regular intervals during prolonged therapy); IOP with therapy >6 weeks. |
|---|
Chemistry & Properties
| Formula | C21H26O5 |
|---|---|
| Molecular weight | 358.43 g/mol |
| IUPAC name | (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione |
| CAS | 53-03-2 |
| PubChem CID | 5865 |
| InChIKey | XOFYZVNMUHMLCC-ZPOLXVRWSA-N |
| logP | 1.77 (XLogP 1.5) |
| Polar surface area | 91.67 Ų |
| H-bond acceptors / donors | 5 / 2 |
| Drug-likeness (QED) | 0.78 |
| Lipinski violations | 0 |
SMILES
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|---|
| Half-life | 2.158 h |
| Volume of distribution | 0.763 L/kg |
| Protein binding | 80.8% |
| BBB penetrant | No |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2C19 | Substrate | — |
| CYP2C8 | Inhibitor | — |
| CYP3A4 | Substrate | — |
Receptor binding (top 1)
| Target | Action | Affinity |
|---|---|---|
| Glucocorticoid receptor (NR3C1) | Agonist | pKi 6.3 |
Transporters
ASBT (Inhibitor)BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)MDR1 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)OATP1A2 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OCT1 (Inhibitor)OCT3 (Inhibitor)P-gp (Inhibitor)MDR1 (Substrate)P-gp (Substrate)
Drug–drug interactions (100+, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Adalimumab | major | |
| Bacillus calmette-guerin substrain tice live antigen | major | |
| Baricitinib | major | |
| Bempedoic acid | major | |
| Brexucabtagene autoleucel | major | |
| Bupropion | major | |
| Certolizumab pegol | major | |
| Cinoxacin | major | |
| Ciprofloxacin | major | |
| Cladribine | major | |
| Deferasirox | major | |
| Delafloxacin | major | |
| Desirudin | major | |
| Desmopressin | major | |
| Dinutuximab | major | |
| Enoxacin | major | |
| Etanercept | major | |
| Fingolimod | major | |
| Gatifloxacin | major | |
| Gemifloxacin | major | |
| Golimumab | major | |
| Grepafloxacin | major | |
| Infliximab | major | |
| Leflunomide | major | |
| Levofloxacin | major | |
| Lomefloxacin | major | |
| Lumateperone | major | |
| Measles virus vaccine live attenuated | major | |
| Mifepristone | major | |
| Moxifloxacin | major | |
| Mumps virus strain B level jeryl lynn live antigen | major | |
| Nalidixic acid | major | |
| Natalizumab | major | |
| Norfloxacin | major | |
| Ofloxacin | major | |
| Ozanimod | major | |
| Rotavirus vaccine | major | |
| Rubella virus vaccine | major | |
| Siponimod | major | |
| Smallpox (Vaccinia) Vaccine, Live | major |
Showing 40 of 100+.
Registered Products (1)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Prednisone 5 Tablets | Tablet 5 mg | 100 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 1.500 |